Bortezomib in multiple myeloma and lymphoma: A systematic review and clinical practice guideline

Current Oncology

Volumn 13, Issue 5, 2006, Pages 160-172

  Reece, Donna ^a   Imrie, K ^b   Stevens, A ^b   Smith, C A ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE

Author keywords

Bortezomib; Clinical practice guideline; Lymphoma; Multiple myeloma; Systematic review; Velcade

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; HUMAN; LYMPHOMA; MEDICAL LITERATURE; MULTIPLE MYELOMA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 33750927701     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Imrie K, Esmail R, Meyer RM, for the Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 2002;136:619-29.
2. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
3. Jagannath S, Barlogie B. Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
4. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
5. Berenson J, Yang H, Swift R, et al. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study [abstract]. Blood 2004;104:209a.
6. Hollmig K. Stover J, Talamo G, et al. Addition of bortezomib (Velcade) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM) [abstract]. Blood 2004;104:929a.
7. Zangari M, Barlogie B, Hollmig K, et al. Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM) [abstract]. Blood 2004;104:1480a.
8. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies [abstract]. Blood 2003;102:1639a.
9. Richardson PG, Chanan-Khan A, Schlossman RL, et al. Phase II trial of single agent bortezomib (Velcade) in patients with previously untreated multiple myeloma (MM) (abstract). Blood 2004;104:336a.
10. Wang LM, Weber DM, Delasalle KB, Alexanian R. VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma [abstract]. Blood 2004;104:210a.
11. Jagannath S, Brian D, Wolf JL, et al. A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma [abstract]. Blood 2004;104:333a.
12. Barlogie B, Hollmig K, Zangari M, et al. Total therapy 3 (TT 3) for newly diagnosed myeloma, incorporating Velcade into remission induction with DT PACE: early results regarding efficacy, PBSC mobilization and toxicities [abstract]. Blood 2004;104:538a.
13. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
14. Goy A, Hart S, Pro B, et al. Report of a phase II study of proteosome inhibitor bortezomib (Velcade) in patients with relapsed or refractory indolent or aggressive lymphomas [abstract]. Blood 2003;102:627a.
15. Strauss SJ, Maharaj L, Stec J, et al. Phase II clinical study of bortezomib (Velcade) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) [abstract]. Blood 2004;104:1386a.
16. Belch A, Kouroukis CT, Crump M, et al. Phase II trial of bortezomib in mantle cell lymphoma [abstract]. Blood 2004;104:608a.
17. Dunleavy K. Janik J, Gea-Banacloche J, et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma [abstract]. Blood 2004;104:1385a.
18. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: final report of the APEX study [abstract]. Blood 2004;104:336a.
19. Dubois D, Ravinder D, van de Velde H, et al. Use of patient-reported outcomes (PROS) to assess prognosis, toxicity, and response: the bonezomib experience in relapsed and refractory multiple myeloma (MM) [abstract]. Blood 2004;104:3468a.
20. Zangari M, Barlogie B, Lee CK. et al. Protective effect of Velcade on thalidomide-associated deep vein thrombosis (DVT) [abstract]. Blood 2004;104:4914a.
21. Zangari M, Barlogie B, Prather J, et al. Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to postautotransplant salvage therapies [abstract]. Blood 2002;100:387a.
22. O'Connor OA, Wright J, Moskowitz C. et al. A multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in sub-type sensitivity to proteasome inhibition [abstract]. Blood 2004;104:607a.
23. Alexanian R, Salmon S, Gutterman J, Dixon D, Bonnet J, Haut A. Chemoimmunotherapy for multiple myeloma. Cancer 1981;47:1923-9.
24. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
25. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6.
26. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
27. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination therapy for refractory multiple myeloma. Br J Haematol 2001;12:991-9.
28. Trieu Y, Trudel S, Pond GR, et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005;80:1578-82.
29. Browman GP, Levine MN, Mohide EA, et al. The Practice Guidelines Development Cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
30. Browman GP, Newman TE, Mohide EA, et al. Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feed-back. J Clin Oncol 1998;16:1226-31.